About Us
Breast cancer is the 2nd leading cause of cancer death in American women. Better, more durable and tolerable therapies are urgently needed.
Our Focus
Advancing (Z)-endoxifen for metastatic breast cancer
Atossa’s immediate strategic focus on metastatic breast cancer reflects both the urgent need in this patient population and a more efficient regulatory path for (Z)-endoxifen to reach patients.
The company is also exploring regulatory pathways for use of (Z)-endoxifen in other indications, including breast cancer prevention and neoadjuvant treatment, where it may serve as a more patient-friendly alternative to tamoxifen.
How does Atossa believe (Z)-endoxifen can address different aspects of the breast cancer continuum? A powerful selective estrogen receptor modulator or SERM, which was developed to be nearly 100 times more potent than other SERMs, with a potentially improved tolerability profile.
- LEARN MORE about the potential for (Z)-endoxifen to transform breast cancer across the treatment continuum
- LEARN MORE about breast cancer
Where innovation meets purpose. Dedicated to transforming breast cancer care with breakthrough science and patient-centric solutions
With a foundation in robust science and a commitment to improving patient outcomes, Atossa is helping to shape a future in which breast cancer is potentially treated more effectively and with fewer side effects—empowering patients at every stage of their journey.
About our name – who was Princess Atossa?
Princess Atossa is recognized as the first known treated case of breast cancer over two millennia ago. Her story reminds us that even in the earliest days of medicine, there was hope—and at Atossa Therapeutics, we carry that legacy forward.
Leadership
Our dedicated team of scientists, clinicians, and industry experts is driven by a singular vision: to improve outcomes and change the narrative for breast cancer patients worldwide.
Interested in exploring a partnership with Atossa Therapeutics?
CONTACT US.
MANAGEMENT TEAM
Steven C. Quay
MD, PHD
Chairman of the Board and Chief Executive Officer
Mark Daniel
Chief Financial Officer
Delly Behen
Senior Vice President, Business Operations
Janet R. Rea, MSPH
Senior Vice President, Research & Development
BOARD of DIRECTORS
Steven C. Quay
MD, PHD
Chairman of the Board and Chief Executive Officer
Shu-Chih Chen, PHD
Director
Tessa Cigler, M.D., M.P.H
Director
Jonathan F. Finn
Director
Stephen J. Galli, MD
Director
H. Lawrence Remmel, ESQ.
Director
